Prokidney (PROK) Debt Ratio (2021 - 2022)
Prokidney (PROK) reported Debt Ratio of 0.0 for Q2 2022, down 99.22% year-over-year from 0.04 in Q2 2021, and up 84.78% quarter-over-quarter from 0.0 in Q1 2022.
Prokidney (PROK) Debt Ratio (2021 - 2022) Analysis & Trends
Prokidney (PROK) has 2 years of Debt Ratio data on file, last reported at 0.0 in Q2 2022.
- Debt Ratio for Q2 2022 came in at 0.0, down 99.22% year-over-year; the trailing twelve-month figure through Jun 2022 was 0.0 (down 99.22% YoY), and the FY2021 annual result was 0.0, changed N/A from the prior year.
- Debt Ratio improved to 0.0 in Q2 2022 per PROK's latest filing, from 0.0 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.04 in Q2 2021 and troughed at 0.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.18 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prokidney | 259.01 Mn | 1.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.04 |